YD Bio (YDES) Assets Average (2025)
YD Bio's (YDES) quarterly Assets Average came in at $9.8 million in Q4 2025, up 54.43% on a QoQ basis from $6.4 million in Q2 2025.
YD Bio (YDES) Assets Average (2025) Analysis & Trends
YD Bio (YDES) has 1 years of Assets Average data on file, last reported at $9.8 million in Q4 2025.
- On a quarterly basis, Assets Average changed N/A year-over-year to $9.8 million in Q4 2025; TTM through Dec 2025 was $9.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.3 million, changed N/A from the prior year.
- Assets Average for Q4 2025 stood at $9.8 million, up from $6.4 million in the prior quarter.
- Over the last five years, Assets Average for YDES reached as high as $9.8 million in Q4 2025 and fell as low as $6.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 65.01 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 40.89 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 8.37 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 2.30 Bn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | 9.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.81 Mn |
| Jun 30, 2025 | 6.35 Mn |